SCROLL through any Filipino social media feed these days and you will see them: the “Tirze journey” posts, the before-and-after photos, the captions about finally fitting into a dress. Tirzepatide is the medicine of the moment. For many plus-size Filipino women, it seems to offer more than weight loss. It offers confidence.
As a plus-size woman who studies how bodies move through public space, I want to take that promise seriously. That means looking at both what the medicine does and what it can’t do.
What the science says
Tirzepatide works on two hormones that regulate appetite and blood sugar. It was first approved for type 2 diabetes and is now registered with the FDA Philippines. Local doctors welcomed it, and the president of Diabetes Philippines called it a possible “game-changer” for the country’s rising obesity rate, if made accessible.
The weight-loss results are hard to dismiss. In SURMOUNT-1, the main trial published in the New England Journal of Medicine, more than 2,500 adults took weekly tirzepatide or a placebo for 72 weeks. Those on the highest dose lost an average of about 21% of their body weight. The placebo group lost about 3%.
The research on daily life matters just as much for this column. Analyses of the SURMOUNT trials found that people on tirzepatide reported better health-related quality of life, especially in physical functioning, and those who lost the most weight reported the biggest gains. In exit interviews from one trial, participants described improvements in many parts of their lives, beyond the number on the scale.
These gains are real. Walking without pain, climbing stairs without stopping, and sitting through a long jeepney ride in comfort: these matter. I won’t dismiss any woman who says the medicine gave her back energy, mobility, or a sense of control over her health.
What the walls are still saying
Still, I keep asking one question: why does confidence so often arrive only after a woman gets smaller?
My research looks at what I call critical body proxemics, which is how public spaces communicate who belongs in them. The narrow chair at the government office. The jeepney seat built for “ten persons, five on each side.” The airplane seatbelt you have to ask an extension for. The tita at the reunion who says, “Tumaba ka!” (“You’ve gotten fat!”) before she says hello. None of these were designed with plus-size women in mind, and all of them send a message: you take up too much room.
When a woman loses weight on tirzepatide, many of those spaces stop sending that message. The chair fits. The comments stop. The confidence she gains is real, but part of it is relief, not transformation. The room didn’t learn to welcome her. She changed to fit the room.
Research on weight stigma backs this up. A large study by Rebecca Pearl, Rebecca Puhl, and colleagues found that internalized weight stigma, the shame we absorb and turn on ourselves, was consistently linked to poorer health outcomes. A survey across six countries found that more than half of adults had experienced weight stigma, and those who blamed themselves were more likely to avoid health care and skip checkups altogether.
Shame keeps women away from doctors, and that can be as dangerous as the weight itself. A weekly injection can change a body. It can’t change a culture that made a woman ashamed of that body.
The biohackers’ bargain
Then there is the price. The registered pen is expensive and paid out of pocket, and that has created a new figure in our online spaces: the “biohacker.” These sellers and self-experimenters offer “unbranded” or compounded tirzepatide, often in vials, at a fraction of the cost. Some post their own weekly results. Others run group chats where women compare doses, side effects, and photos.
I understand why this appeals to plus-size women. Many tell stories of real change: clothes that fit, less knee pain, finally eating without the constant “food noise.” Some say it is the first time anything has worked for them. Those stories deserve respect. They also tell us something important. When the safe option is out of reach, women will take the risk anyway, because the shame of living in a body the world doesn’t welcome feels worse than the danger.
Still, a testimonial is not a study. As of this writing, Mounjaro KwikPen is the only tirzepatide product approved by the FDA Philippines. Neither the buyer nor the seller can be sure what’s actually inside an unbranded vial: how strong it is, how clean it is, or whether it is tirzepatide at all. The FDA Philippines has warned the public against unregistered tirzepatide products. The Philippine College of Physicians has cautioned that compounded versions have not gone through clinical trials or regulatory review, and selling them may violate the Pharmacy Law.
So I won’t shame the women who chose this route. I’ll ask a different question: why should a Filipino woman have to gamble with her health just to afford a chance at confidence? The answer isn’t only stronger crackdowns on sellers. It’s making the legitimate medicine affordable, bringing obesity care within reach through PhilHealth and public clinics, and building a culture where women don’t feel so desperate to shrink in the first place.
The cautions we owe each other
The research gives us other reasons to be careful. First, tirzepatide works only as long as you take it. In the SURMOUNT-4 trial, participants who stopped regained a substantial amount of weight, while those who continued kept losing. Women should start knowing it is likely a long-term treatment, not a quick fix before a wedding or a class reunion.
Second, look at who was studied. In SURMOUNT-1, about two-thirds of participants were women, but around 70% were white. Filipino and other Southeast Asian women were a small minority. Many of the quality-of-life analyses were also written by researchers employed by the drug’s manufacturer. That doesn’t make the findings false. It does mean we need Filipino-led, independent research on how this medicine affects our own women’s bodies, budgets, and sense of self.
Making room
The DOST-FNRI reports that obesity among Filipino adults aged 20 to 59 rose to 44.5% in 2025, nearly half of working-age adults. We are not a minority to be fixed one injection at a time. We ride the jeepneys, sit in the offices, and fill the classrooms.
So my position is this. If a woman and her doctor decide tirzepatide is right for her health, she deserves our support, not judgment, and she deserves access to safe, affordable, properly supervised treatment. But confidence should not have to be bought, injected, or earned by getting smaller.
Spaces speak. A city with wider seats, a clinic where doctors don’t lecture, a family table where nobody comments on your plate: these say you belong here, at any size. The medicine may change our bodies. It’s still up to us to change our rooms.
–
Kethelle I. Sajonia is a college instructor at the University of Southeastern Philippines (USeP), Mintal Campus. She holds a Doctor of Communication and a Master of Development Communication degree from the University of the Philippines. Her research interests encompass inclusive communication, education, gender and development, social equity, and community development. She is currently working as an educator, researcher, and advocate for inclusion, contributing to research, publications, and community-based initiatives that further equitable, culturally responsive, and transformative communication. Much of her research focuses on how communication relates to identity and inclusion, specifically on sharing the voices that need to be heard to create meaningful social change.


